Abstract | BACKGROUND: OBJECTIVE: Here we have further studied the effect of RAPTA-EA1 on BRCA1-defective HCC1937 breast cancer cells and compared its effects on BRCA1-competent MCF-7 breast cancer cells. METHOD: HCC1937 and MCF-7 breast cancer cells were treated with the RAPTA-EA1 complex. The cytotoxicity of ruthenium-induced cells was evaluated by a MTT assay. Cellular uptake of ruthenium was determined by ICP-MS. Cell cycle and apoptosis were assessed using a flow cytometer. Expression of BRCA1 mRNA and its encoded protein was quantitated by a real-time RT-PCR and Western blotting. RESULTS: Differences in cytotoxicity were correlated with the differential accumulations of ruthenium and the induction of apoptosis. The ruthenium complex caused dramatically more damage to the BRCA1 gene in the BRCA1-defective HCC1937 cells than to the BRCA1-competent MCF-7 cells. It decreased the expression of BRCA1 mRNA in the BRCA1-competent cells, while in contrast, its expression increased in the BRCA1-defective cells. However, the expression of the BRCA1 protein was significantly reduced in both types of breast cancer cells. CONCLUSION: The results presented here have demonstrated a differential cellular response for the BRCA1-defective and BRCA1-competent breast cancer cells to RAPTA-EA1. These findings have provided more insight into the actions and development of the ruthenium-based compounds for use for the treatment of breast cancer.
|
Authors | Adisorn Ratanaphan, Tidarat Nhukeaw, Khwanjira Hongthong, Paul J Dyson |
Journal | Anti-cancer agents in medicinal chemistry
(Anticancer Agents Med Chem)
Vol. 17
Issue 2
Pg. 212-220
( 2017)
ISSN: 1875-5992 [Electronic] Netherlands |
PMID | 27039925
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- BRCA1 Protein
- BRCA1 protein, human
- Organometallic Compounds
- RNA, Messenger
- Ruthenium
|
Topics |
- Antineoplastic Agents
(chemistry, pharmacokinetics, pharmacology)
- Apoptosis
(drug effects)
- BRCA1 Protein
(genetics)
- Breast Neoplasms
(drug therapy, genetics, pathology)
- Cell Line, Tumor
- Down-Regulation
(drug effects)
- Female
- Genes, BRCA1
(drug effects)
- Humans
- MCF-7 Cells
- Organometallic Compounds
(chemistry, pharmacokinetics, pharmacology)
- RNA, Messenger
(genetics)
- Ruthenium
(chemistry, pharmacokinetics, pharmacology)
|